Evolut R

La coronariografía precoz reduce la mortalidad en SCA sin supradesnivel del ST de alto riesgo

Long-Term Evolution of Hybrid Coronary Revascularization

Currently, myocardial revascularization surgery (MRS) and percutaneous coronary intervention (PCI) are the available strategies for multivessel coronary artery disease. However, an alternative strategy has long been developed, called hybrid coronary revascularization (HCR), where the anterior descending artery is bypassed with a graft from the mammary artery and the rest of the lesions are treated byref="https://solaci.org/en/2023/01/23/long-term-evolution-of-hybrid-coronary-revascularization/" title="Read more" >...

valve_in_valve-compressor

Valve-in-Valve Shows Good Evolution after 2 Years

The degeneration of bioprostheses in aortic position occurs at approximately after 10 to 15 years. In this scenario, the treatment of choice used to be redo surgery, but with the evolution of transcatheter aortic valve replacement (TAVR), it became a valid alternative with a level IIa B evidence. While there are currently multiple analyses ofref="https://solaci.org/en/2022/12/02/valve-in-valve-shows-good-evolution-after-2-years/" title="Read more" >...

El cierre de orejuela es seguro con los nuevos dispositivos

Do Men and Women Present the Same Evolution after Left Atrial Appendage Closure?

Atrial fibrillation is a very frequent type of arrythmia that affects both men and women alike. This entity is associated to higher mortality seeing as it favors stroke and hospitalization for cardiac failure.  At present, one of its valid treatment strategies is left atrial appendage closure, to reduce or prevent stroke and anticoagulation driven bleeding. ref="https://solaci.org/en/2022/11/14/do-men-and-women-present-the-same-evolution-after-left-atrial-appendage-closure/" title="Read more" >...

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | TriCLASP, Evolution at 30 Days

Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low.  Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patientsref="https://solaci.org/en/2022/05/26/europcr-2022-triclasp-evolution-at-30-days/" title="Read more" >...

Claudicación Intermitente: ¿el tratamiento invasivo es superior al tratamiento farmacológico?

Coronary Angioplasty Evolution According to Syntax II: 5-Year Followup

It has been long since the SYNTAX (NEJM 2009) came out comparing percutaneous coronary intervention (PCI) against coronary artery bypass grafting (CABG). That emblematic study associated PCI with first generation drug eluting stents (Taxus) with increased major cardiac and cerebrovascular events (all-cause mortality, AMI, stroke, or any revascularization – MACCE) vs. CABG, at 5 years,ref="https://solaci.org/en/2022/05/05/coronary-angioplasty-evolution-according-to-syntax-ii-5-year-followup/" title="Read more" >...

Trombólisis local en tromboembolismo pulmonar

Device Evolution Also Impacts on Valve in Valve

TAVR to treat dysfunctional biological prosthetics (ViV) with the last generation self-expandable supra-annular prosthetic offers excellent results both clinical and hemodynamic. In addition, there were additional reductions of paravalvular regurgitation compared against the original models.  The present registry published in JAHA is the most extensive to treat this issue and replicate outcomes from the clinicalref="https://solaci.org/en/2021/10/21/device-evolution-also-impacts-on-valve-in-valve/" title="Read more" >...

Evolut Low Risk

EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies. This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress andref="https://solaci.org/en/2021/05/27/europcr-2021-evolut-low-risk-two-year-results-of-the-self-expanding-valve-in-low-risk-patients/" title="Read more" >...

TCT 2020 | La Acurate Neo no alcanza la no inferioridad vs la CoreValve Evolut

TCT 2020 | Acurate Neo Does Not Meet Non-Inferiority vs. CoreValve Evolut

The self-expanding Acurate Neo (Boston Scientific) did not meet non-inferiority vs. the self-expanding CoreValve Evolut (Medtronic) in the SCOPE 2 study published in Circulation simultaneously and presented at the virtual TCT 2020. These are bad news for the Acurate Neo, that had already failed to show non-inferiority vs. the Sapien 3 in the SCOPE 1ref="https://solaci.org/en/2020/10/21/tct-2020-acurate-neo-does-not-meet-non-inferiority-vs-corevalve-evolut/" title="Read more" >...

Válvula Bicúspide

Good Evolution of Bicuspid Valves with EVOLUTE or EVOLUTE PRO

Courtesy of Dr. Carlos Fava. TAVR has matured over time and has advanced onto low risk patients, but one of its greatest challenges continues to be bicuspid valve patients. These represent between 1% and 2% of the population and over 20% of young adults requiring surgical valve replacement (SAVR).  The study looked at 27,086 patientsref="https://solaci.org/en/2020/08/28/good-evolution-of-bicuspid-valves-with-evolute-or-evolute-pro/" title="Read more" >...

Top